|Event Name||OMICS Group 2016 Asia Pacific Drug Formulation & Bioavailability Congress
Wednesday, November 02, 2016
Friday, November 04, 2016
DoubleTree by Hilton Beijing
|Description||OMICS Group is organizing Asia Pacific Drug Formulation & Bioavailability Congress during November 02-04, 2015 Beijing, China.
Drug Formulation is a process in Pharmaceutics. Formulation means compounding of single or combination of active ingredients, excipients like Fillers, Disintegrants, Lubricants, Glidants, and Binders etc., packed in a single pack to form a Pharmaceutical Drug. Formulation deals with Active Pharmaceutical Ingredient to Packaging of the finished product which means Analytical R & D, Formulation R & D, Blending, Drying, Punching or Filling, Packaging. Formulation may be in different dosage forms like Oral Dosage Forms, Parenteral Dosage Forms and Topical Dosage Forms. Pharmaceutical formulation is the development of a bioavailable, stable and optimal dosage form for a specific administration route.
In the light of this theme, the conference series aims to provide a forum for international researchers from various areas of biomedical, Pharmaceutical, and clinical sciences by providing a platform for critical analysis of new data, and to share latest cutting-edge research findings and results about all aspects of Drug Formulation.
China’s changing health-care environment is designed to extend basic health insurance to a larger portion of the population and give individuals greater access to products and services. Following this period of change, the pharmaceutical industry is expected to continue its expansion. According to IMS Health Inc., China is currently the third largest pharmaceutical market in the world, posting $67 billion in revenue in 2011. With an anticipated compound growth rate of 24 percent between 2010 and 2020, China is expected to be the second largest market by 2015. Currently, there are about 1,400 drug companies in China that are, collectively, able to produce more than 60 dosage forms and about 5,000 different types of medicines. The current Chinese market value of the dosage form medicines is worth about $50 B, accounting for about 5.7% of the global market value. Internally, aiming to transform the Chinese pharmaceutical industry, the Chinese government is encouraging the Chinese drug companies to upgrade their manufacturing facility and improve their product quality. It is therefore believed that the Chinese dosage form drug market will continue to grow in a fast pace. It is expected to likely experience a CAGR of about 25% in the next five years. Its market value could reach more than $150 B by 2015.
OMICS International Organises 300+ Conferences Every Year across USA, Europe & Asia with support from 1000 more scientificsocieties and Publishes 400+ Open access journals which contains over 30000 eminent personalities, reputed scientists as editorial board members.